Илиадин спрей в нос в турции инструкция по применению

Имидин Н капли: инструкция по применению

Description

Active Ingredient

At the heart of Iliadin Merck Pediatrik Spray lies the active ingredient, oxymetazoline hydrochloride, a vasoconstrictor renowned for its prowess in reducing swelling within the nasal passages. This key component serves as the linchpin in alleviating nasal congestion, whether stemming from the common cold, sinusitis, or syringitis. The formulation also includes a roster of inactive ingredients, such as benzalkonium chloride, disodium EDTA, sodium hydroxide, sodium dihydrogen phosphate dihydrate, disodium hydrogen phosphate 12-hydrate, and deionized water.

Proper Usage: Instructions

The judicious use of Iliadin Merck Pediatrik Spray is paramount. Prior to application, it is imperative to meticulously peruse the instructions and adhere to them with precision. Should questions arise, consulting a healthcare professional, be it a doctor or pharmacist, is advisable. Importantly, the nasal spray should only grace the nostrils of the individual for whom it was prescribed, never to be shared with others.

Contraindications

While Iliadin Merck Pediatrik Spray is a potent ally against nasal congestion, certain individuals should proceed with caution or avoid its use altogether. This includes those with allergies to any of its ingredients or to other adrenergic drugs. Moreover, individuals grappling with a unique nasal mucosa inflammatory condition known as rhinitis sicca, or those hypersensitive to benzalkonium chloride (a preservative in the spray), should eschew its use. Additionally, individuals who have undergone transsphenoidal hypophysectomy (removal of the pituitary gland through the nose) or surgery leaving their meninges (dura mater) exposed should refrain from employing this spray.

Side Effects:

As with any medication, Iliadin Merck Pediatrik Spray may unveil side effects in some individuals. In such instances, promptly reaching out to a healthcare provider, whether doctor or pharmacist, for guidance is advised. These side effects may encompass burning sensations, stinging, increased nasal discharge, dryness within the nasal cavity, sneezing, nervousness, nausea, dizziness, headache, and challenges falling or staying asleep. It is crucial to bear in mind that not everyone will experience these side effects, and their intensity may vary.

Storing the Nasal Spray Securely

Ensuring the safe storage of Iliadin Merck Pediatrik Spray is paramount. It should be sheltered from light and maintained at or below 25°C. Additionally, taking measures to keep the spray out of children’s reach is essential, promoting both safety and peace of mind.

Accidental Exposure: Eyes and Mouth

In the event of accidental contact between the nasal spray and the eyes or mouth, swift action is crucial. Thoroughly rinsing the affected area with water is advised. Should any discomfort or irritation persist, consulting a healthcare professional, whether doctor or pharmacist, is recommended. Adhering to the instructions with precision, even in such unforeseen situations, is a hallmark of responsible medication usage.

Conclusion

Iliadin Merck Pediatrik Sprey stands as a trusted ally for parents seeking to alleviate their child’s nasal congestion woes. Its potent formulation, combined with meticulous adherence to usage instructions and vigilance for potential side effects, makes it a valuable asset in the realm of pediatric healthcare. However, caution is the watchword, with certain contraindications warranting careful consideration. Consulting a healthcare professional remains the best course of action to ensure safe and effective usage.

Use the form below to report an error

Please answer the questions as thoroughly and accurately as possible. Your answers will help us better understand what kind of mistakes happen, why and where they happen, and in the end the purpose is to build a better archive to guide researchers and professionals around the world.

Wikikenko.com does not sell, distribute, or provide any pharmaceutical products or health services. Our platform functions solely as a health encyclopedia, providing information on a wide range of health topics, including but not limited to medications.

Medical Disclaimer: Seek Professional Advice

The information on this page is not intended to be a substitute for professional medical advice, diagnosis, or treatment. always seek the advice for your physician or another qualified health provider with any questions you may have regarding a medical condition. Always remember to

1. Ask your own doctor for medical advice.
2. Names, brands, and dosage may differ between countries.
3. When not feeling well, or experiencing side effects always contact your own doctor.

Why you can’t look for symptoms on the Internet

If diagnoses could be made simply from a textbook or an article on a website, we would all be doctors and treat ourselves. Nothing can replace the experience and knowledge of specially trained people. As in any field, in medicine there are unscrupulous specialists, differences of opinion, inaccurate diagnoses and incorrect test results. According to Wikipedia, cyberchondria is a mental disorder consisting in the desire to independently make a diagnosis based on the symptoms of diseases described on Internet sites.

Iliadin 0.025% is a direct-acting sympathomimetic which has vasoconstrictor effect on mucosal blood vessels when applied topically and in turn reduces oedema of the nasal mucosa.

Iliadin 0.025% is an adrenergic α1- and α2-agonist and a direct-acting sympathomimetic drug. By stimulating adrenergic receptors, oxymetazoline causes vasoconstriction of dilated arterioles and reduces blood flow. In a radioligand competition study, oxymetazoline displayed higher affinity at α1A-adrenoceptors compared to α2B-adrenoceptors, but with higher potency at α2B-adrenoceptors. When sprayed intranasally, oxymetazoline relieved relief nasal congestion and improved nasal airflow in patients with acute coryzal rhinitis for up to 12 hours following a single dose.

An early in vitro study demonstrated oxymetazoline to exert anti-oxidant actions, where it inhibited microsomal lipid peroxidation and mediated hydroxyl radical scavenging activity. This suggests that oxymetazoline has a beneficial effect against oxidants, which play a role in tissue damage in inflammation.

Uses

Iliadin 0.025% Hydrochloride is applied topically to relieve nasal congestion associated with acute or chronic rhinitis, common cold, sinusitis, and hay fever or other allergies. It is also used as nasal decongestant in otitis media.

Iliadin 0.025% is also used to associated treatment for these conditions:
Acquired Blepharoptosis, Allergic Rhinitis (AR), Nasal Congestion, Postoperative Hemorrhages, Rhinorrhoea, Sinus Congestion, Acute Rhinitis, Persistent facial erythema, Airway visualization

How Iliadin 0.025% works

Iliadin 0.025% binds to α₁— and α₂-adrenoceptors, which are Gq-protein-coupled receptors that promote vascular smooth muscle contraction by increasing intracellular calcium levels in response to ligand activation.

Rosacea is a condition characterized by transient and persistent facial erythema. By stimulating α_1A-adrenoceptors and causing vasoconstriction, oxymetazoline is believed to diminish the symptoms of erythema. In blepharoptosis, it is hypothesized that oxymetazoline works by stimulating α-adrenergic receptors on the Müller muscle that elevates the upper eyelid, causing muscle contraction. Iliadin 0.025% is used in combination with tetracaine for local anesthesia in dentistry. Such combination use adds beneficial effects: the vasoconstrictor counteracts the local anesthetic agent’s vasodilatory action, thereby constricting dilated arterioles and reducing blood flow to the application area. Iliadin 0.025% relieves nasal congestion by vasoconstricting the respiratory microvasculature, in both resistance and capacitance blood vessels on the human nasal mucosa, leading to decreased nasal mucosal blood flow, edema, and airflow resistance.

Dosage

Adults and children 6 years of age and older: 2-3 drops or sprays in each nostril twice daily for 3-5 days.

Children of age 2-6 years: 2-3 drops in each nostril twice daily for 3-5 days. Sprays are generally unsuitable for young children because of the small size of their nostrils. The drug is not recommended in children under the age of 2 years.

The nasal spray can be used with the patient in the upright position. Sprays are generally unsuitable for young children because of the small size of their nostril. A treatment course should not normally exceed three to five days, and on no account should it be continued for longer than two weeks because of the risk of developing «rhinitis medicamentosa».

Side Effects

Transient burning, dryness of the nasal mucosa, sneezing, Nervousness, dizziness, headache, Hypertension, palpitation or reflex bradycardia.

Toxicity

In rats, the oral LD₅₀ is 680 ug/kg and the subcutaneous LD₅₀ is 1630 ug/kg. In mice, the oral LD₅₀ is 4700 ug/kg, the intraperitoneal LD₅₀ is 48 mg/kg, and the subcutaneous LD₅₀ is 34 mg/kg.

Case reports have documented unintended overdose in both children and adults: overdose has led to dizziness, chest pain, headaches, myocardial infarction, stroke, visual disturbances, arrhythmia, hypertension, or hypotension. Accidental ingestion of topical solutions of imidazoline derivatives, including oxymetazoline, in children has resulted in serious adverse events requiring hospitalization, such as nausea, vomiting, lethargy, tachycardia, decreased respiration, bradycardia, hypotension, hypertension, sedation, somnolence, mydriasis, stupor, hypothermia, drooling, and coma. Possible rebound nasal congestion, irritation of nasal mucosa, and adverse systemic effects (particularly in children), including serious cardiovascular adverse events, have been reported with overdosage as well as prolonged or too frequent intranasal use of oxymetazoline. Overdose should be responded with close monitoring, supportive care, and symptomatic treatment.

Precaution

• Prolonged use may result in rebound congestion.
• Since oxymetazoline has systemic adverse effects, it should be used with caution in patients with
• Hypertension, cardiovascular disease or hyperthyroidism or in those receiving MAO inhibitors.

Interaction

Monoamine oxidase inhibitors (MAOIs): Concomitant use of oxymetazoline and MAOI can result in hypertensive reaction.

Tricyclic antidepressants (TCAs): TCAs may increase the effects of oxymetazoline on blood pressure.

Food Interaction

No interactions found.

Volume of Distribution

There is limited information on the volume of distribution of oxymetazoline.

Elimination Route

Imidazole derivatives such as oxymetazoline are readily absorbed across mucosal membranes, especially in children. In adult subjects with erythema associated with rosacea, the mean ± standard deviation (SD) C_max was 60.5 ± 53.9 pg/mL and the AUC from time 0 to 24 hours (AUC_0-24hr) was 895 ±798 pg x hr/mL following topical administration of first-dose oxymetazoline. Following once-daily topical applications for 28 days, the mean ± SD C_max was 66.4 ± 67.1 pg/mL and the AUC_0-24hr was 1050 ± 992 pg x hr/mL. Following twice-daily applications for 28 days, the mean ± SD C_max was 68.8 ± 61.1 pg/mL and the AUC_0-24hr was 1530 ± 922 pg x hr/mL.

Following single-drop ocular administration of oxymetazoline in healthy adult subjects, the mean ± SD C_max was 30.5 ± 12.7 pg/mL and the area under the concentration-time curve (AUC_inf) was 468 ± 214 pg x hr/mL. The median T_max was 2 hours, ranging from 0.5 to 12 hours.

Following nasal administration of an 0.6 mL combination product containing tetracaine and oxymetazoline in adult subjects, the maximum concentrations of oxymetazoline were reached within approximately 10 minutes. The mean C_max was 1.78 ng/mL and the AUC_0-inf value was 4.24 ng x h/mL, with a median Tmax of 5 minutes.

Half Life

Following ocular administration in healthy adults, the mean terminal half-life was 8.3 hours, ranging from 5.6 to 13.9 hours.

The terminal half-life of oxymetazoline following nasal administration of the combination product containing tetracaine and oxymetazoline in adult subjects is approximately 5.2 hours.

Clearance

There is limited information on the clearance rate of oxymetazoline.

Elimination Route

While the excretion of oxymetazoline following nasal, topical, or ophthalmic administration of oxymetazoline has not been fully characterized in humans, it is believed that the predominant route of elimination at clinically relevant concentrations of oxymetazoline is renal excretion.

Pregnancy & Breastfeeding use

Pregnancy: Safe use of oxymetazoline during pregnancy has not been established; it should be avoided by pregnant women.

Nursing Mother: It is not known whether oxymetazoline is secreted in human breast milk; caution is advised.

Contraindication

Contraindicated in patients hypersensitive to Oxymetazoine Hydrochloride.

Acute Overdose

Following a proper application, systemic action is unlikely. If, however, some of the drops are swallowed, systemic effect can be produced. Symptoms include rapid, irregular heartbeat, headache, dizziness, increased sweating, nervousness. Such symptoms are more likely to be seen in young children.

Innovators Monograph